CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
Axon Enterprise (AXON) Vs Palantir Technologies (PLTR): Which is the Better Investment?
Strong Q2 results have led to a further uproar in Axon Enterprise AXON and Palantir Technologies PLTR shares this week, remaining two of the hottest momentum stocks. Axon's stock has now spiked over +40% year to date, with Palantir shares surging more than +130%. More astonishing, AXON is up over +640% in the last three years with PLTR skyrocketing more than 1,700%. Considering their millionaire-maker-like gains, investors are surely wondering which of these hot stocks is the better investment at the moment. Axon Thrives on Increased Public Safety Spending Thanks to increased global defense and public safety spending, Axon easily surpassed its Q2 expectations while posting stellar top and bottom line growth. The innovative manufacturer of weapons for the U.S. and international governments posted Q2 sales of $668.54 million, which soared nearly 33% year over year and comfortably topped estimates of $642.98 billion by 4%. Furthermore, this marked the 14 th consecutive quarter of revenue growth above 25%, with CEO Rick Smith stating Axon is seeing broad demand across the company's portfolio, including for its AI services, drones, cameras, and virtual reality solutions. More impressive, Axon's Q2 earnings came in at $2.12 per share, crushing expectations of $1.54 by 37% and soaring 76% from $1.20 in the prior period. Axon has now exceeded the Zacks EPS Consensus for a remarkable 33 consecutive quarters, with a very impressive average earnings surprise of 25.87% in its last four quarterly reports. Palantir's First Billion-Dollar Quarter Also thriving from increased defense spending, including the securement of a $10 billion contract with the U.S. Army, Palantir achieved its first-ever billion-dollar quarter, topping estimates of $938.33 million. This was a 48% spike from Q2 sales of $678.13 million a year ago, as the software provider saw strong demand for its artificial intelligence platform (AIP) outside of the intelligence communities. Pinpointing increased commercial demand for AIP, Palantir CEO Alex Karp stated that companies are using Palantir's tools not just to optimize operations, but to reshape entire business models. Palantir is also taking advantage of its expansive sales growth, with Q2 EPS of $0.16 rising from $0.09 a share in the comparative quarter and edging expectations of $0.14. Notably, Palantir has now reached of exceeded the Zacks EPS Consensus for 11 consecutive quarters with an average earnings surprise of 13.17% over the last four quarters. Axon & Palantir Raise Their Full-Year Guidance Adding fuel to investor sentiment is that Axon and Palantir have raised their full-year revenue guidance. Optimistically, Axon now forecasts fiscal 2025 revenue at $2.65-$2.73 billion, up from $2.6-$2.7 billion. It's also noteworthy that Axon expects full-year adjusted EBITDA of $665-$685 million, raised from $650-$675 million. Pivoting to Palantir, the company raised its FY25 revenue forecast to $4.142 billion-$4.15 billion, up from previous guidance of $3.89 billion-$3.9 billion. The bump is specifically attributed to full-year commercial revenue guidance increasing to over $1 billion, reflecting at least 85% growth. Additionally, Palantir raised its adjusted income from operations guidance to between $1.912 billion-1.92 billion and increased its adjusted free cash flow guidance to $1.8 billion-$2 billion. Monitoring Axon & Palantir's Valuation While Axon is well ahead in terms of moving further past the probability line than Palantir, the price-to-sales ratio may still be a better indicator of judging the value these hot stocks offer to investors at their current levels, rather than price-to-earnings. That said, Axon is also growing into its lofty valuation more swiftly regarding the P/S ratio after a rebranding to reflect its broader mission in public safety technology. To that point, Axon trades at 25X forward sales, which is far more reasonable than Palantir's 104X. Conclusion & Final Thoughts Although Palantir's ability to benefit from the AI boom makes it the better momentum stock at the moment, Axon appears to be the overall better investment when considering its more justifiable valuation. Axon's profitability also makes it a more sound investment, and earnings estimate revisions (EPS) have remained higher, correlating with AXON sporting a Zacks Rank #1 (Strong Buy). On the other hand, Palantir stock lands a Zacks Rank #3 (Hold), and investors may certainly be looking for better entry points given PLTR doesn't offer much fundamental value after such a monstrous year-to-date rally. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON): Free Stock Analysis Report
CTV News
7 minutes ago
- CTV News
PM, premiers strategize next steps in trade war
Vancouver Watch Prime Minister Mark Carney met with premiers to talk tariffs and the ongoing trade war with the U.S. Here's what happened.
CBC
8 minutes ago
- CBC
RFK Jr.'s move to axe $500M in vaccine funding slammed
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has announced a $500-million cut to funding for mRNA vaccine development, insisting the technology used in COVID-19 vaccines poses risks. Many medical experts say the reasoning is untrue and could slow development of future vaccinations.
